Table 3

Characteristics of anti-TNF treated patients with lymphoma/leukaemia

Treatment Initiating year	Sex	Year of birth	Rheumatic disease		Previous DMARD*	Continuing DMARD at anti-TNF initiation	Therapeutic response to anti-TNF	Tumour diagnosis		Outcome course Oct 2003
Treatment Initiating year	Sex	Year of birth	Diagnosis	Onset	Previous DMARD*	Continuing DMARD at anti-TNF initiation	Therapeutic response to anti-TNF	Time of diagnosis	Anti-TNF treatment day at diagnosis	Outcome course Oct 2003
*MTX, methotrexate; SSZ, sulfasalazine; ciclosp, ciclosporin; ama, antimalarial drugs; gold IM, injectable gold; gold oral, auranofin; CYC, cyclophosphamide.
Infliximab	M	1923	RA	1972	2	0	+?	Hodgkin	129	Fatal
July 2000–Nov 2000					SSZ, ama			Nov 2000		Nov 2000

Infliximab Apr 2000–Dec 2002	F	1926	RA, keratitis	1978	2 MTX, CYC	MTX	++	Non-Hodgkin Maxilla	180	Alive
								Oct 2000

Infliximab Feb 2000–Sep 2001	F	1943	RA	1989	6 MTX, SSZ, gold IM and oral, ama	0	+++	Non-Hodgkin, B-lcc, inguinal	570	Alive
								Sep 2001

Infliximab, then etanercept Mar 1999–Sep 1999, Sep 1999-Aug 2002, respectively	F	1954	RA	1989	5 MTX, SSZ ciclosp, gold IM, penicillamine	MTX	+++	MALT, lung Aug 2002	1081	Fatal Postmortem MALT diagnosis in Aug 2002

Etanercept Apr 1999–Dec 1999	F	1918	RA	1994	3 MTX, SSZ, gold IM	0	+?	Immuno-cytoma, breast Dec 1999	220	Fatal June 2000

Etanercept Apr 1999–July 2000	M	1925	RA	1976	1 MTX	MTX	++	Acute myeloic leukaemia, trisomi 8 chromosome	440	Moved abroad, fatal Jan 2002
								Nov 2000